{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-26-000021","form_type":"8-K/A","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.865442+00:00","generated_at":"2026-05-15T06:55:10.573234+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mirum completes acquisition of Bluejay Therapeutics with $268.5M PIPE; Bluejay reports 2025 net loss of $101.7M","bullets":["Concurrent PIPE raised $268.5M gross at $68.48/sh including pre-funded warrants.","Bluejay 2025 audited: net loss $101.7M, R&D $87.1M, total assets $85.6M, accumulated deficit $190M.","Bluejay had substantial doubt about going concern; Mirum committed to fund operations post-close.","Lead candidate brelovitug (BJT-778) for chronic hepatitis delta is in clinical development.","Pro forma financials for combined entity filed; acquisition closed Jan 23, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-26-000021","json":"https://secwatch.observer/filing/0001759425-26-000021.json","markdown":"https://secwatch.observer/filing/0001759425-26-000021.md","text":"https://secwatch.observer/filing/0001759425-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000021/0001759425-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000021/mirm-20260123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:55:10.573234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}